Obesity – Standards, trends and advances

This publication has 71 references indexed in Scilit:

• Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss
  JAMA, 2023
• Glucagon-modified Liposomes Delivering Thyroid Hormone for Anti-obesity Therapy
  Archives of Medical Research, 2023
• Obesity and gut–microbiota–brain axis: A narrative review
  Journal of Clinical Laboratory Analysis, 2022
• Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study
  Drug Safety, 2021
• Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic
  Obesity, 2021
• Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity
  JAMA Network Open, 2021
• Magnetic resonance imaging of obesity and metabolic disorders: Summary from the 2019 ISMRM Workshop
  Magnetic Resonance in Medicine, 2019
• Association of Mirabegron With the Risk of Arrhythmia in Adult Patients 66 Years or Older—A Population-Based Cohort Study
  JAMA Internal Medicine, 2019
• Effect of bimagrumab on thigh muscle volume and composition in men with casting‐induced atrophy
  Journal of Cachexia, Sarcopenia and Muscle, 2017
• The ratio of visceral to subcutaneous fat, a metric of body fat distribution, is a unique correlate of cardiometabolic risk
  Diabetologia, 2012